

~Cystic Fibrosis ~

Prior Authorization Request Form

In order for members to receive Medicaid coverage for medications that require prior authorization, the prescriber must complete and fax this form to Change Healthcare. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information. For questions, please contact the Change Healthcare helpdesk at 1-844-679-5363.

Submit request via Fax: 1-844-679-5366

Prescribing physician:	Beneficiary:	
Name:	Name:	
Physician NPI:	Medicaid ID#:	
Specialty:	Date of Birth:	Sex:
Phone#:	Patient's Phone:	
Fax#:	Pharmacy Name	
Address:	Pharmacy NPI:	
Contact Person at Office:	Pharmacy Phone:	Pharmacy Fax:

The following MUST be completed for MEDICAL BENEFIT requests:

HCPCS J-code or other code:		
Administering Provider/Facility: Name	NPI#	Medicaid ID#

Please check box if this drug is being provided under the DVHA's 340B Drug program and requires the TB modifier 🗆

Patient Diagnosis:
Cystic Fibrosis
Other:

(Requires Review by DVHA Medical Director)

Mucolytics:

□ Bronchitol[®] (mannitol) capsules for inhalation

Inhale the contents of 10 capsules (400mg) twice daily

□ Pulmozyme[®] (dornase alfa inhalation) 1 mg/ml, 2.5 ml ampules

Administer via nebulizer once daily	Dispense# 30	Refill	times
Administer via nebulizer twice daily	Dispense# 60	Refill	times

Inhaled Antibiotics:

Preferred Agents:

Bethkis® (tobramycin) Solution: Administer via nebulizer twice daily, alternating 28 days on and 28 days off

□ Kitabis[®] (tobramycin) Solution: Administer via nebulizer twice daily, alternating 28 days on and 28 days off

□ Tobramycin Solution for inhalation 300mg/5mL ampules: Administer via nebulizer twice daily, alternating 28 days on and 28 days off

□ TOBI[®] (tobramycin) Podhaler 28 mg capsules (capsules for use with Podhaler only, requires prior trial of another form of inhaled tobramycin): Administer 4 capsules via Podhaler twice daily, alternating 28 days on and 28 days off

Non-preferred Agents (documentation must be submitted including reasons why the preferred products cannot be used):

Cayston[®] (aztreonam) Solution: Administer via nebulizer three times daily, alternating 28 days on and 28 days off

□ TOBI[®] (tobramycin solution for inhalation) 300mg/5 mL ampules: Administer via nebulizer twice daily, alternating 28 days on and 28 days off

□ Tobramycin Solution for inhalation 300mg/4mL ampules: Administer via nebulizer twice daily, alternating 28 days on and 28 days off





CFTR Gene Mutation Potentiators:
🗆 Kalydeco® (ivacaftor) packets 🗆 50mg (less than 14kg) 🛛 🗆 75mg (greater than 14kg)
□ Kaludaca® (ivacaftar) 150mg tablats
Kalydeco [®] (ivacaftor) 150mg tablets
Directions
□ Orkambi® (lumacaftor/ivacaftor) tablets □ 100/125mg □ 200/125mg
🗆 Orkambi® (lumacaftor/ivacaftor) Packets 🛛 100/125mg (less than 14kg) 🛛 🖓 150/188mg (greater than 14kg)
Directions
□ Symdeko® (Tezacaftor/Ivacaftor & Ivacaftor) □ 50/75mg □ 100/150mg
Directions
□ Trikafta® (Elexacaftor/Tezacaftor/Ivacaftor & Ivacaftor) □ 50/25/37.5 and 75mg □ 100/50/75 and 150mg
Directions
By completing this form, I hereby certify that the above request is true, accurate and complete. That the request is medically necessary, does not exceed the medical needs of the member, and is
clinically supported in the patient's medical records. I also understand that any misrepresentations or concealment of any information requested in the prior authorization request may subject me to audit and/or recoupment.

Prescriber's Signature: _____ Date: _____

